23 September 2009
Interim Results for the six months to 30 June 2009
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce its Interim Results for the six months to 30 June 2009.
Highlights
- Five products currently in development, comprising both medical devices and pharmaceuticals predominantly focused on the over the counter market
- CSD500 - Completion of manufacturing data progressing prior to European marketing authorisation
- PET500 - Positioning of enhanced sexual control means a shorter regulatory process and potential for early launch in the USA subject to finalisation of a commercial agreement
- TPR100 - Evaluation agreement signed in July 2009 with major pharmaceutical company
- Pre-tax loss of £0.7 million for the six months ended 30 June 2009 (H1 2008: Pre-tax loss of £1.1 million)
- Cash of £1 million at 30 June 2009 (31 December 2008: £0.8 million)
James Barder, Futura Medical's Chief Executive, said: "Progress to date in 2009 continues to reinforce our confidence in the future. CE mark approval for CSD500 is anticipated around the end of the year. We are also excited by the rapid progress on PET500, and on progress elsewhere in our pipeline of opportunities."
The full results are available to download in PDF format.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com
Nominated Adviser:
Nomura Code Securities Limited
Phil Walker / Giles Balleny
Tel: +44 (0) 20 7776 1200
For media enquiries please contact:
Buchanan Communications Limited
Mark Court / Stasa Filiplic / George Prassas
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.